About United Therapeutics (UTHR)

United Therapeutics (UTHR) has a market capitalization of $15.01B. The average daily trading volume is 416.64K, indicating the stock's liquidity and investor engagement.

The current price per share for United Therapeutics (UTHR) is $338.22. The stock has seen a price change of $1.85 recently, indicating a 0.55% change. This reflects the stock's recent market performance and investor sentiment.

For United Therapeutics (UTHR), the 52-week high is $343.98, which is 1.7% from the current price. The 52-week low is $208.62, the current price is 62.12% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

United Therapeutics (UTHR) has shown an average price growth of 0.41% over the past three years. It has received a score of 65 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying United Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, United Therapeutics (UTHR) has a year-to-date price change of 48.77%. Over the past month, the stock has experienced a price change of 6.01%. Over the last three months, the change has been 43.34%. Over the past six months, the figure is 54.21%. Looking at a longer horizon, the five-year price change stands at 339.93%.

United Therapeutics (UTHR) has a net income of $984.8M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.94% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 52.58% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.33B, with a revenue growth rate of 20.2%, providing insight into the company's sales performance and growth. The gross profit is $2.07B. Operating income is noted at $1.18B. Furthermore, the EBITDA is $1.49B.